Botox treatment for migraine and chronic daily headache in adolescents

Journal of Neuroscience Nursing

Volumn 41, Issue 5, 2009, Pages 235-243

  Chan, Valerie W ^a   Mccabe, E Jane ^a   Macgregor, Daune L ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADOLESCENT; ARTICLE; FEMALE; FOLLOW UP; HEADACHE AND FACIAL PAIN; HUMAN; MIGRAINE WITHOUT AURA; NURSING; OFF LABEL DRUG USE; PAIN ASSESSMENT; PATIENT SATISFACTION; QUALITY OF LIFE; TREATMENT OUTCOME;

ADOLESCENT; BOTULINUM TOXIN TYPE A; FEMALE; FOLLOW-UP STUDIES; HEADACHE DISORDERS; HUMANS; MIGRAINE WITHOUT AURA; NEUROMUSCULAR AGENTS; OFF-LABEL USE; PAIN MEASUREMENT; PATIENT SATISFACTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 73349117817     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/JNN.0b013e3181aaa98f     Document Type: Article

References (45)

1. Aguggia, M. (2008). Treating headaches with botulinum toxin. Neurological Science, 29, S137-S139.
2. Aoki, K. R. (2001). Pharmacology and immunology of botulinum toxin serotypes. Journal of Neurology, 248 (Suppl. 1), 3-10.
3. Aoki, K. R. (2003). Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache, 43 (Suppl. 1), S9-S15. (Pubitemid 36988542)
4. Ashkenazi, A., & Silberstein, S. (2008). Botulinum toxin type A for the treatment of headache: Why we say yes. Archives of Neurology, 65 (1), 146-149.
5. Barrientos, N., & Chana, P. (2003). Botulinum toxin type A in prophylactic treatment of migraine headaches: A preliminary study. Journal of Headaches and Pain, 4, 146-151. (Pubitemid 38029031)
6. Binder, W., Brin, M. F., Blitzer, A., Schoenrock, L. D., & Pogoda, J. M. (2000). Botulinum toxin type A for treatment of migraine headaches: An open label study. Otolaryngology Head and Neck Surgery, 123 (6), 669-676.
7. Blumenfeld, A. (2003). Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache, 43 (8), 853-860. (Pubitemid 37108342)
8. Blumenfeld, A. M., Binder, W., Silberstein, S. D., & Blitzer, A. (2003). Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache, 43, 884-891. (Pubitemid 37108346)
9. Burstein, R., Yarnitsky, D., Goor-Aryeh, I., Ransil, B., & Bajwa, Z. H. (2000). An association between migraine and cutaneous allodynia. Annals of Neurology, 47, 614Y624.
10. Dodick, D. W., Mauskop, A., Elkind, A. H., DeGryse, R., Brin, M. F., Silberstein, S. D., et al. (2005). Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache, 45, 315-324. (Pubitemid 40530195)
11. Dolly, O. (2003). Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache, 43 (Suppl. 1), S16-S24. (Pubitemid 36988543)
12. Durham, P. L., Cady, R., & Cady, R. (2004). Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache, 44 (1), 35-42, discussion 42-43.
13. Edvinsson, L. (2001). Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache. CNS Drugs, 15, 745-753.
14. Edvinsson, L., & Goadsby, P. J. (1994). Neuropeptides in migraine and cluster headache. Cephalalgia, 14, 320-327. (Pubitemid 24335355)
15. Friedman, A. P. (1972). The headache in history, literature and legend. Bulletin of the New York Academy of Medicine, 48, 661-81.
16. Gladstone, J. P., & Dodick, D. W. (2004). From hemicrania lunaris to hemicrania continua: An overview of the revised International Classification of Headache Disorders. Headache, 44 (7), 692-705.
17. Goadsby, P. J., & Edvinsson, L. (1993). The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology, 33, 48-53.
18. Goadsby, P. J., & Edvinsson, L. (1994). Human in vivo evidence for trigeminal activation in cluster headache: Neuropeptide changes and effects of acute attack therapies. Brain, 11 7, 427-434. (Pubitemid 24225892)
19. Gobel, H. (2004). Botulinum toxin in migraine prophylaxis. Journal of Neurology, 251 (Suppl. 1), 18-11.
20. Gunner, K. B., & Smith, H. D. (2007). Practice guideline for diagnosis and management of migraine headaches in children and adolescents: Part one. Journal of Pediatric Health Care, 21, 327-332.
21. Gunner, K. B., Smith, H. D., & Ferguson, L. E. (2008). Practice guideline for diagnosis and management of migraine headaches in children and adolescents: Part two. Journal of Pediatric Health Care, 22, 52-59.
22. Guyuron, B., Rose, K., Kriegler, J. S., & Tucker, T. (2004). Hourglass deformity after botulinum toxin type A injection. Headache, 44 (3), 262-264. (Pubitemid 38436691)
23. Hohne-Zell, B., Galler, A., Schepp, W., Gratzl, M., & Prinz, C. (1997). Functional importance of synaptobrevin and SNAP-25 during exocytosis of histamine by rat gastric enterochromaffinlike cells. Endocrinology, 138, 5518-5526. (Pubitemid 28012282)
24. Jancovic, J., & Brin, M. F. (1997). Botulinum toxin: Historical perspective and potential new indications. Muscle and Nerve. Supplement, 6, S129-S145.
25. Lewis, D. W. (2007). Headaches in children and adolescents. Current Problems in Pediatrics and Adolescent Health Care, 37, 207-246.
26. Lewis, D. W., Ashwal, S., Dahl, G., Dorbad, D., Hirtz, D., Prensky, A., et al. (2002). Practice parameter: Evaluation of children and adolescents with recurrent headaches: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 59 (4), 490-8.
27. Lewis, D. W., Ashwal, S., Hershey, A., Hirtz, D., Yonker, M., & Silberstein, S. (2004). Practice parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology, 63, 2215-2224. (Pubitemid 40024327)
28. Lewis, D. L., Yonker, M., Winner, P., & Sowell, M. (2005). The treatment of pediatric migraine. Pediatric Annals, 34, 449-460.
29. Lipton, R. B., Stewart, W. F., & Simon, D. (1998). Medical consultation for migraine: Results from the American Migraine Study. Headache, 38 (2), 87-96. (Pubitemid 28155226)
30. Malick, A., & Burstein, R. (2000). Peripheral and central sensitization during migraine. Functional Neurology, 15 (Suppl. 3), 28-35. (Pubitemid 32051372)
31. Martin, A. L., McGrath, P. A., Brown, S. C., & Katz, J. (2007). Anxiety, sensitivity, fear of pain and pain-related disability in children and adolescents with chronic pain. Pain Research and Management, 12, 267-272. (Pubitemid 351255911)
32. Mathew, N. T., Frishberg, B. M., Gawel, M., Dimitrova, R., Gibson, J., Turkel, C., et al. (2005). Botulinum toxin type A (Botox ®) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache, 45, 293-307. (Pubitemid 40530193)
33. McGrath, P. (1989). Evaluating a child's pain. Journal of Pain and Symptom Management, 4 (4), 198-214. (Pubitemid 20080031)
34. Oleson, J. (2004). The international classification of headache disorders. Cephalalgia, 24 (Suppl. 1), 1-160.
35. Ondo, W. G., Vuong, K. D., & Derman, H. S. (2004). Botulinum toxin A for chronic daily headache: A randomized, placebo-controlled, parallel design study. Cephalalgia, 24 (1), 60-65.
36. Parker, C. (1997). Complicated migraine syndromes and migraine variants. Pediatric Annals, 26 (7), 417-421. (Pubitemid 27527858)
37. Patrick, D. L., Hurst, B. C., & Hughes, J. (2000). Further development and testing of the migraine-specific quality of Life (MSQOL) measure. Headache, 40 (7), 550-560. (Pubitemid 30497413)
38. Rothner, A. D. (1999). Headaches. In K. F. Swaiman & S. Ashwal (Eds.), Pediatric neurology: Principles & practice (3rd ed., pp. 747-758). St. Louis, MO: CV Mosby.
39. Schim, J. (2004). Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. Current Medical Research and Opinion, 20 (1), 49-53. (Pubitemid 38063455)
40. Schulte-Mattler, W. J., Krack, P., & BoNTTH Study Group. (2004). Treatment of chronic tension-type headache with botulinum toxin A: A randomized, double-blind, placebocontrolled multi-center study. Pain, 109 (1-2), 110-114.
41. U. S. Food and Drug Administration: Center for Drug Evaluation and Research. (2008). Early communication about an ongoing safety review of Botox and Botox cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). Retrieved February 19, 2008, from www.fda.gov/cder/drug/early-comm/ botulinium-toxins.htm
42. Virtanen, R., Aromaa, M., Rautava, P., Metsahonkala, L., Anttila, P., Helenius, H., et al. (2007). Changing headache from preschool age to puberty: A controlled study. Cephalalgia, 27, 294-303.
43. Winner, P. K. (1997). Headaches in children: When is a complete diagnostic workup indicated? Postgraduate Medicine, 101 (5), 81-85, 89-90.
44. Winner, P., Martinez, W., Mate, L., & Bello, L. (1995). Classification of pediatric migraine: Proposed revisions to the IHS criteria. Headache, 35 (7), 407-410.
45. Youssef, N. N., Murphy, T. G., Langseder, A. L., & Rosh, J. R. (2006). Quality of life for children with functional abdominal pain: A comparison study of patients' and parents perceptions. Pediatrics, 11 7 (1), 54-59.